EMA Recommends Granting a Marketing Authorisation for Aumolertinib By Ogkologos - January 8, 2026 88 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with EGFR-mutated NSCLC Source RELATED ARTICLESMORE FROM AUTHOR Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours MOST POPULAR Adding Avelumab to Preoperative Chemoradiotherapy Provides Promising Anti-Tumour Activity in Locally... July 8, 2021 New Device Could “Hear” Stiffening of Extracellular Matrix to Determine Where... April 2, 2020 Trametinib Is a New Treatment Option for Rare Form of Ovarian... March 10, 2022 EMA Recommends Granting a Conditional Marketing Authorisation for Tafasitamab July 8, 2021 Load more HOT NEWS A urine test for bladder cancer: What’s the latest? Can Artificial Intelligence Help See Cancer in New, and Better, Ways? Preparing for your COVID-19 Vaccine: What to Ask your Provider Efficacy and Safety of Adding Antiangiogenesis Therapy to First-Line Immunochemotherapy in...
